Evidence map›Paper›PMID 34452934›Full record

ArticleBMJ open respiratory research2021

One time a day mometasone/indacaterol fixed-dose combination versus two times a day fluticasone/salmeterol in patients with inadequately controlled asthma: pooled analysis from PALLADIUM and IRIDIUM studies.

Kenneth Chapman, Richard van Zyl-Smit, Jorge Maspero, Huib A M Kerstjens, Yasuhiro Gon, Motoi Hosoe, Ana-Maria Tanase, Abhijit Pethe, Xu Shu, Peter D'Andrea

2 registry-linked trialsOpen access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMJ open respiratory research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.5field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02554786 phase3completednot on this map

A Multicenter Randomized 52 Week Treatment Double-blind, Triple Dummy Parallel Group Study to Assess the Efficacy and Safety of QMF149 Compared to Mometasone Furoate in Patients With Asthma

TypeinterventionalSponsorNovartis PharmaceuticalsRan2015 to 2019Enrolled2,216ConditionsAsthmaArmsIndacaterol acetate/Mometasone furoate, Mometasone furoate, Salmeterol xinafoate/fluticasone propionate
NCT02571777 phase3completednot on this map

A Multicenter, Randomized, 52-week, Double-blind, Parallelgroup, Active Controlled Study to Compare the Efficacy and Safety of QVM149 With QMF149 in Patients With Asthma

TypeinterventionalSponsorNovartis PharmaceuticalsRan2015 to 2019Enrolled3,092ConditionsAsthmaArmsQVM149 150/50/160, QVM149 150/50/80, QMF149 150/320, QMF149 150/160, salmeterol/fluticasone
3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 7 citations in OpenAlex.

  1. Observational
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 6 institutions in 6 countries.

Kenneth ChapmanDivision of Respiratory Medicine, Department of Medicine, University of Toronto, Toronto, Ontario, Canada ken.chapman.airways@gmail.com.
Richard van Zyl-SmitDivision of Pulmonology and UCT Lung Institute, Department of Medicine, University of Cape Town, Cape Town, South Africa.
Jorge MasperoAllergy and Respiratory Research Unit, Fundación Centro Investigacion de Enfermedades Alergicas y Respiratorias, Buenos Aires, Argentina.
Huib A M KerstjensDepartment of Pulmonology, University of Groningen, University Medical Center Groningen, and Groningen Research Institute for Asthma and COPD, Groningen, The Netherlands.
Yasuhiro GonDivision of Respiratory Medicine, Department of Internal Medicine, Nihon University School of Medicine, Tokyo, Japan.
Motoi HosoeNovartis Pharma AG, Basel, Switzerland.
Ana-Maria TanaseNovartis Pharma AG, Basel, Switzerland.
Abhijit PetheNovartis Pharmaceuticals Corporation, East Hanover, New Jersey, USA.
Xu ShuNovartis Pharmaceuticals Corporation, East Hanover, New Jersey, USA.
Peter D'AndreaNovartis Pharmaceuticals Corporation, East Hanover, New Jersey, USA.ORCID 0000-0001-9831-1568
Novartis (United States) · USNovartis (Switzerland) · CHNihon University · JPUniversity Medical Center Groningen · NLUniversity of Cape Town · ZAUniversity of Toronto · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundDespite currently available standard-of-care inhaled corticosteroid (ICS)/long-acting β

methodsThis analysis included patients from PALLADIUM (NCT02554786) and IRIDIUM (NCT02571777) studies who received high-dose MF/IND (320/150 µg) or medium-dose MF/IND (160/150 µg) one time a day or high-dose FLU/SAL (500/50 µg) two times a day for 52 weeks. Reduction in asthma exacerbations, improvement in lung function, asthma control, and safety were evaluated for 52 weeks.

resultsIn total, 3154 patients (high-dose MF/IND, n=1054; medium-dose MF/IND, n=1044; high-dose FLU/SAL, n=1056) were included. High-dose MF/IND showed 26%, 22% and 19% reductions in rate of severe, moderate or severe, and all (mild, moderate and severe) exacerbations versus high-dose FLU/SAL, respectively, over 52 weeks (all, p<0.05). High-dose MF/IND improved trough FEV

conclusionsOne time a day, single-inhaler, high-dose MF/IND reduced asthma exacerbations and improved lung function versus two times a day, high-dose FLU/SAL in patients with inadequately controlled asthma. Similarly, improved outcomes were seen with one time a day, medium-dose MF/IND and two times a day, high-dose FLU/SAL, but at a lower ICS dose.

Indexed as

AsthmaDrug CombinationsFluticasone-Salmeterol Drug CombinationHumansIndansMometasone FuroateQuinolonesDrug CombinationsFluticasone-Salmeterol Drug CombinationindacaterolIndansMometasone FuroateQuinolonesasthmaasthma in primary careasthma pharmacology

Identifiers

PMID34452934
PMCPMC8404447
OpenAlexW3193503969

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.